Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.7K
5.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Late cytopenia after CD19 chimeric antigen receptor T cell in large B cell lymphoma: A Cell Therapy Consortium Analysis.

Blood advances·2026
Same author

Management of Bispecific Antibody Toxicities: A Focus on Multiple Myeloma.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial).

Frontiers in oncology·2026
Same author

CAR T-Cell Kinetics, Persistence and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-Cell ALL Treated with Obecabtagene Autoleucel in the FELIX Study.

Cancer research communications·2026
Same author

Outcomes and Safety of CAR-T Cell Therapy in B-NHL Patients With Reduced Left Ventricular Ejection Fraction.

Transplantation and cellular therapy·2026
Same author

Low-Strength Type I Interferon Signaling Promotes CAR T Cell Treatment Efficacy.

Cancer immunology research·2026

Related Experiment Video

Updated: Apr 6, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

Update on checkpoint blockade therapy for lymphoma.

Justin Kline1, Michael R Bishop2

  • 1Department of Medicine, University of Chicago, 5841 S. Maryland Ave., MC2115, Chicago, IL 60637 USA ; Committee on Immunology, University of Chicago, Chicago, IL USA.

Journal for Immunotherapy of Cancer
|July 23, 2015
PubMed
Summary
This summary is machine-generated.

Tumors evade immune attack through mechanisms like PD-1/PD-L1 interactions. Blocking these interactions shows promise in treating Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.2K
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

22.2K

Related Experiment Videos

Last Updated: Apr 6, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

6.2K
Flow Cytometry-based Assay for the Monitoring of NK Cell Functions
08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

22.2K

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Tumors utilize immune evasion strategies to escape host immune responses.
  • While studied in solid tumors, hematologic malignancies also employ local environmental cues for immune escape.
  • Key immune checkpoints, Programmed Death-1 (PD-1) and Cytotoxic Lymphocyte Antigen-4 (CTLA-4), regulate T cell function.

Purpose of the Study:

  • To review mechanisms of PD-L1 expression in lymphoma.
  • To summarize early clinical trial results of PD-1 blockade therapy in lymphoma.

Main Methods:

  • Review of scientific literature on PD-L1 expression and PD-1 blockade in lymphoma.
  • Analysis of early-phase clinical trial data for Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

Main Results:

  • PD-1 ligands are over-expressed in select HL and NHL subtypes, often due to genetic amplification.
  • Other mechanisms contributing to PD-L1 over-expression in lymphoma have been identified.
  • Early clinical trials indicate significant effectiveness of PD-1 blockade in HL and activity in some NHLs.

Conclusions:

  • PD-1/PD-L1 pathway dysregulation is a critical immune evasion mechanism in lymphoma.
  • PD-1 blockade represents a promising therapeutic strategy for lymphoma patients.